At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
Пилотный проект по ранней диагностике рака легких на основе КТ-снимков пациентов с подозрением на COVID-19 завершился на базе областного клинического онкологического диспансера в Нижнем Новгороде.
SAN DIEGO, June 25, 2021 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that Scott Oross has been appointed as General Counsel.
SEATTLE–Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.
